pathway for these products. Companies must first assess which component—the drug or the device—contributes most significantly to the intended use, which can help determine how to classify the product.

Both the Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH) have jurisdiction over combination products, impacting how submissions are approached. It is vital to consult the FDA’s guidelines on combination products, which describe the nuances in submitting applications.

Ultimately, an understanding of the components and intended uses of your combination product plays a critical role in navigating the submission process.

Step 2: Conducting a Regulatory Pathway Assessment

Once the combination product is defined, conducting a regulatory pathway assessment is the next important step. The key here is to identify whether a single application (NDA/BLA with device information) or a dual application (separate PMA/510(k) submissions) is appropriate.

Factors to consider in the assessment include:

• Intended Use: Determine the primary purpose of the product—does it act primarily as a drug or a device?
• Regulatory History: Examine any existing data from similar combination products and their approval processes.
• Risk Profile: Consider the risk associated with the product. Devices typically undergo varying levels of scrutiny based on their risk categorization (Class I, II, or III).

The first approach is to classify the product through the FDA’s Combination Product Request for Designation (RFD). The RFD provides a formal mechanism to obtain clarity on product classification and product jurisdiction for both the drugs and devices. The RFD process can also yield information regarding the most suitable application strategy.

Once the primary mode of action is determined and the RFD is obtained, submitters can proceed to define the specific regulatory strategy tailored for either the single or dual application paths.

Step 3: Preparing for Submission Documentation

Once the preferred regulatory pathway is determined, comprehensive documentation preparation is critical. Each path has its respective requirements that must be carefully adhered to, including:

Single Application Preparation (NDA/BLA with Device Info)

When preparing a single application, companies must provide complete details on the combination product, ensuring to include:

• Product Description: A thorough description that encompasses both the drug and device components, their interactions, performance, and safety.
• Clinical Data: Robust clinical evidence demonstrating safety and efficacy for both aspects of the combination product, including clinical trial design specifics.
• Quality Data: Information concerning the manufacturing processes, controls, and stability studies for both drug and device components.

Additionally, the FDA requires combination-specific considerations, such as how the product adheres to the Quality System Regulation for devices, and that the labeling of the product clearly indicates the drug-device relationship.

Dual Application Preparation (Separate PMA/510(k))

For separate applications, companies must differentiate the documents according to the requirements for each submission:

• PMA Requirements: This detailed documentation must include the complete clinical studies performed to gain PMA approval, along with evidence of controls and validation performed on the manufacturing processes.
• 510(k) Requirements: A traditional 510(k) submission must include substantial equivalence to a legally marketed device. It must elaborate on how the device functions and communicate any differences from the predicate device.

Thorough preparation at this stage sets the foundation for a successful submission. Utilizing submission checklists provided by the FDA for each type can streamline document assembly and ensure compliance with regulatory expectations.

Step 4: Submission of NDA/BLA or PMA/510(k)

With comprehensive documentation finalized, companies can proceed to submission. Each application type follows a rigorous submission process to ensure compliance with regulatory standards:

NDA/BLA Submission

This process typically involves:

• Filing the New Drug Application or Biologics License Application through the FDA’s Electronic Submissions Gateway.
• Including all requisite forms, such as a Form 356h, which is pivotal for both drug and biologic product submissions.
• Ensuring sufficient user fees are paid, as mandated under the Prescription Drug User Fee Act (PDUFA).

Once submitted, the FDA begins an initial review, often reaching out to the sponsor for additional information, which may extend the review timeline. It’s important to respond promptly to any queries to keep the application on track for approval.

PMA/510(k) Submission

When submitting a PMA or 510(k), companies must ensure:

• A clear indication of whether it is a full PMA submission or a 510(k) for substantial equivalence.
• Delivery through the FDA’s electronic system for device submissions, ensuring adherence to appropriate formatting guidelines.
• Rigorous assessments of the device’s risk categorization and compliance with applicable standards.

It’s critical to be prepared for potential follow-up communications and to have the ability to provide additional data if required, as the review may lead to inquiries that demand swift responses.

Step 5: Review Process and Addressing FDA Queries

Post-submission, the FDA engages in a comprehensive review process for all applications. It generally takes between 6 to 12 months for drug applications, while device submissions may vary based on classification and review type.

During this time, the following actions are recommended:

• Track the progress of the review through the FDA’s system and maintain regular communication with the agency.
• Be prepared for potential advisory committee meetings, especially in cases where complex combination products are involved.
• Develop responses to any queries promptly, ensuring all requested information is addressed to avoid prolonged delays in the review process.

Effective management of this review phase is essential for maintaining timelines and aligning developmental goals with regulatory expectations.

Step 6: Post-Approval Commitments and Compliance

Upon receiving approval, manufacturers should be prepared for ongoing compliance obligations, which vary depending on whether a single or dual strategy was employed.

For NDA/BLA holders, post-approval commitments may include:

• Post-Market Surveillance: Commitment to monitoring the safety and effectiveness of both drug and device components once on the market.
• Annual Reports: Submission of detailed annual reports covering safety data, manufacturing changes, and product distribution.

Meanwhile, PMA holders must adhere to rigorous requirements, which involve:

• Implementation of a Quality Management System (QMS): Ensuring adherence to ongoing manufacturing standards and device performance.
• Handling of Adverse Events: Complying with reporting obligations regarding any adverse events associated with the device component.

Companies must stay informed about changing regulations and enforcement standards to ensure compliance remains intact throughout the product lifecycle.

In summary, the choice between a single or dual application strategy can notably impact the regulatory landscape for combination products. Utilizing this guide, regulatory affairs, quality assurance, and clinical research teams can make informed decisions that align with their organizational goals while maintaining compliance with FDA regulations.

For further guidelines and resources, consult the FDA’s Office of Combination Products, which provides invaluable information on this subject.